Previously a relatively unknown drug to North American athletes, Furazabol gained notoriety in the
Commission of Inquiry into the Use of Drugs and Banned Practices Intended to Increase Athletic Performance (known colloquially as the
Dubin inquiry). After winning the 100m gold at the
1988 Summer Olympics in Seoul, Canadian sprinter
Ben Johnson tested positive for the anabolic steroid
Stanozolol, was later stripped of his gold medal, and banned from competition for two years. Johnson initially denied the allegations, asserting he had never taken banned substances. He later claimed the positive finding was the result of sabotage, and that he had actually taken Furazabol, which at the time could not be detected by the
Gas Chromatography-Mass Spectrometry assay used to analyze samples at the Games. Contrariwise, Stanozolol had been widely used in elite athlete circles since the 1970s, and as of 1988, could be reliably identified by conventional testing procedures. Testifying before the Dubin Inquiry, Johnson's physician
George "Jamie" Astaphan claimed that he had been administering Furazabol (which he termed Estragol) to Johnson since the mid-1980s, and that Johnson likely self-administered Stanozolol within a month of the Games opening in Seoul. In later testimony, Johnson's training mate
Angella Issajenko told the Commission that she too had obtained Furazabol from Astaphan, or so she thought. The former-Canadian record holder revealed that, after Johnson's positive test, she had an analysis done on a leftover vial of what she thought contained Furazabol, and was informed it was identified as Stanozolol. Issajenko, and later the Commission's Chief Justice Charles Dubin, concluded Astaphan had been peddling Stanozolol to Johnson, Issajenko, and other Canadian team members all along, and that Furazabol was either a figment of his imagination, or an outright lie. ==References==